© 2021 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
November 30, 2021
Dana Chase, MD, discusses frontline therapy options for patients with advanced ovarian cancer.
Karen Reckamp, MD, and Jyoti Patel, MD, review currently available frontline treatment options for ALK+ advanced NSCLC and discuss updated efficacy and safety data from key clinical trials of these agents in advanced NSCLC.
Jyoti Patel, MD, elucidates the mechanism of action of various ALK targeting agents in NSCLC and the optimal formulations and dosing strategies in patients with advanced NSCLC.
Treatment advice for community oncologists and hematologists who treat follicular lymphoma based on therapeutic advances occurring rapidly in the field.
Treatment options and variables that need to be considered when managing patients with follicular lymphoma who relapse early after first-line chemoimmunotherapy.
Factors that affect the use of maintenance therapy, including anti-CD20 maintenance therapy, for newly diagnosed follicular lymphoma, and recommendations for assessing response to therapy.
The rationale for treating newly diagnosed follicular lymphoma with the anti-CD20 monoclonal antibody, obinutuzumab, in the first-line setting.
Goals of therapy and variables that affect how patients with newly diagnosed follicular lymphoma are managed with chemoimmunotherapy in the frontline setting, including during COVID-19.
Recommendations for assessing and risk stratifying patients with newly diagnosed follicular lymphoma, with special considerations regarding the current role of molecular testing.
Similarities between the management of a hypothetical case of newly diagnosed follicular lymphoma compared with what is done in real-world practice.